Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:17:07.588Z.
Consensus retrieved: 2026-10-06T12:42:49.944Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:17:07.588Z.
Quote observation: 2026-10-06T14:03:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 01663dfca956974affc1f8a19269627919b7b0574d072734ca03f9e3c91e02f4
Forward PE Ratio (N/A) = Dated Quote Price ($1.24) / Consensus Forward EPS ($-2.36)
FORWARD PE RATIO
N/A
Imunon, Inc.
Market Cap
$5.21M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Imunon, Inc. (IMNN) | $5.21M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.21M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.29M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.10M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.10M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.33M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.35M | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.96M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.55M | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.83M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.24, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.36 | $-2.88 – $-1.73 | 3 | n/m |
| 2027-12-31 | $-1.82 | $-2.72 – $-0.95 | 3 | n/m |
| 2028-12-31 | $-1.36 | $-1.84 – $-1.05 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
